RxDoctor Payments Data

Harold Giles, MD

Nephrology · Homewood, ALNPI 1811945454

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $14,600 of the $17,721 with a category attached, or 82.4%. 10 manufacturers reported payments, led by Nxstage Medical, Inc. at 55.6% of the total. Reporting peaked in 2022 at $8,369 and has fallen 99.7% since, to $26 in 2025.

$17,721in general payments, 2019–2025

Across 46 payments — averaging $385.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nxstage Medical, Inc.$10K
  • Fresenius USA Marketing, Inc.$7K
  • Akebia Therapeutics Inc$286
  • Amgen$142
  • AstraZeneca$99
  • Travere Therapeutics, Inc.$22
  • plus $70 from 4 others

What the payments were for

  • Consulting fees$14,60082%
  • Travel & lodging$1,5419%
  • Food & beverage$1,5609%
  • Education$200%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,721 in reported general payments places this provider in the 85th percentile of 164 nephrology providers in Alabama.

See all nephrology providers in Alabama

Medicare billing

Part B allowed, 2024
$222,000
Medicare patients
446
Services billed
2,460

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AuryxiaFerric Citrate38$122,053
FarxigaDapagliflozin Propanediol170$113,602
VelphoroSucroferric Oxyhydroxide14$39,286
JardianceEmpagliflozin21$17,975
Sevelamer Carbonate96$15,953
KerendiaFinerenone11$6,997
Calcium Acetate75$6,729
Potassium Chloride220$6,358
Furosemide250$4,828
Nystatin111$2,930
Gentamicin Sulfate86$2,680
Calcitriol132$2,628
Telmisartan49$1,728
Clonidine11$917
Cinacalcet Hcl14$906

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Akebia Therapeutics IncAuryxia$286$122,05338 claims
AstraZenecaFarxiga$99$113,602170 claims
Fresenius USA Marketing, Inc.Velphoro$7,252$39,28614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 164 nephrology providers in Alabama.

Other nephrology in Homewood

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →